Jefferies raised the firm’s price target on Amgen to $380 from $375 and keeps a Buy rating on the shares. For Q2, the firm sees a slight beat beat on revenues and EPS and potential bump up in guidance, adding that it continues to like Amgen for “best new moneyflow” on obesity and upcoming catalysts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen price target raised to $337 from $307 at UBS
- Jefferies healthcare analyst holds an analyst/industry conference call
- Truist biotech analyst holds an analyst/industry conference call
- Amgen price target lowered to $303 from $310 at Morgan Stanley
- Ideaya Biosciences price target raised to $60 from $53 at Oppenheimer